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Abstract
Background: The aim of this study was to estimate both the direct and indirect annual costs of
treating bacterial conjunctivitis (BC) in the United States. This was a cost of illness study performed
from a U.S. healthcare payer perspective.
Methods: A comprehensive review of the medical literature was supplemented by data on the
annual incidence of BC which was obtained from an analysis of the National Ambulatory Medical
Care Survey (NAMCS) database for the year 2005. Cost estimates for medical visits and laboratory
or diagnostic tests were derived from published Medicare CPT fee codes. The cost of prescription
drugs was obtained from standard reference sources. Indirect costs were calculated as those due
to lost productivity. Due to the acute nature of BC, no cost discounting was performed. All costs
are expressed in 2007 U.S. dollars.
Results: The number of BC cases in the U.S. for 2005 was estimated at approximately 4 million
yielding an estimated annual incidence rate of 135 per 10,000. Base-case analysis estimated the total
direct and indirect cost of treating patients with BC in the United States at $ 589 million. One- way
sensitivity analysis, assuming either a 20% variation in the annual incidence of BC or treatment
costs, generated a cost range of $ 469 million to $ 705 million. Two-way sensitivity analysis,
assuming a 20% variation in both the annual incidence of BC and treatment costs occurring
simultaneously, resulted in an estimated cost range of $ 377 million to $ 857 million.
Conclusion: The economic burden posed by BC is significant. The findings may prove useful to
decision makers regarding the allocation of healthcare resources necessary to address the
economic burden of BC in the United States.
Background
Natural history
Bacterial conjunctivitis is a microbial infection of the
mucous membrane of the conjunctiva of the eye and can
occur in both adults and children. It is produced by an
array of microorganisms, with the most common bacterial
pathogenic organism worldwide being Staphylococcus
aureus [1-4]. Other prominent bacterial species include:
Streptococcus pneumoniae and  Haemophilus influenzae,
while other Staphyloccocus species, Moraxella species and
opportunistic bacteria are more typically seen in the
chronic forms of bacterial conjunctivitis [1-4]. Haemo-
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philus influenzae is the most common isolate in children
less than seven years of age [4]. In persons with symptoms
of conjunctivitis, who are sexually active, they may be
infected with either gonorrhea or chlamydia. In most
instances, the infection begins unilaterally, with the fel-
low eye becoming involved within a few days. Although,
it is typically considered a minor infection, bacterial con-
junctivitis can have a considerable impact on school
attendance, lost work time and very occasionally, can
result in permanent or sight-threatening sequelae such as
bacterial keratitis and endophthalmitis in extreme cases
[5,6].
Epidemiology
Although the literature on the epidemiology of bacterial
conjunctivitis contains several references to its highly con-
tagious nature [7-10] no overall population-based data
exists on the incidence of bacterial conjunctivitis. In the
United States it is estimated that 23% of bacterial conjunc-
tivitis cases occur in the 0-2 year age range, 28% occur in
the 3-9 year range, 13% occur in the 10-19 year range with
the remaining 36% of cases occurring in adults [11,12].
Existing clinic-based estimates from Norway, have calcu-
lated that the prevalence of the most severe form of acute
infective bacterial conjunctivitis is on the order of 30 out
of 1000 patients in a general medical practice, though a
correct diagnosis was only made in about two-thirds of
these cases [13]. Similar clinic-based data from the United
Kingdom have pointed to a rise in the proportion of
patients who have sought medical attention for conjunc-
tivitis, rising from 284 per 10,000 in 1981-1982 to 395
per 10,000 over the period 1991-1992 [14]. It has further
been estimated that acute bacterial conjunctivitis repre-
sents up to 1% of all visits to general practitioners in the
United Kingdom [15]. However, it has also been noted
that general practitioners tend to over-diagnosis bacterial
conjunctivitis [15] due to the difficulties of differentiating
between the bacterial and viral forms of the disease. In
2002 a survey of general practitioners in the United King-
dom found that only 36% felt that they could correctly
differentiate between acute bacterial and viral conjunctivi-
tis. Additionally, 95% of the physicians surveyed indi-
cated they prescribed topical antibiotics to patients with
suspected bacterial conjunctivitis [16].
Existing Economic Evidence
The treatment and management of U.S. bacterial conjunc-
tivitis patients has never been fully quantified and the
costs incurred by the healthcare system remain largely
unknown. Several studies found that in both the Nether-
lands and the United Kingdom, 900,000 and 3.4 million
prescriptions, respectively, for topical ocular antibiotics
were issued at a cost of £5.9 million and £4.7 million,
respectively. However, these studies included all aetiolo-
gies which gave rise to a prescription for topic ocular anti-
biotics and were not necessarily due to bacterial
conjunctivitis [17-19]. It is against this background, that
the current study attempts to estimate the annual cost of
healthcare resource utilization attributable to the manage-
ment of bacterial conjunctivitis in the United States.
Cost of Illness Studies
The economic impact of a given disease is commonly
measured as an aggregate of both the direct and indirect
costs associated with treating and managing patients with
the given condition. A third category of "intangible costs"
or costs due to pain and suffering are sometimes included
in the overall panoply of costs. However, in practice intan-
gible costs are difficult to quantify and are typically not
considered. Direct costs are defined as the value of goods
and services used in the treatment, care, and rehabilitation
of a given illness or injury [20-23]. Indirect costs are
defined as the value of economic output lost because of
illness, injury-related work disability, or premature death
[20-23]. Additionally, indirect costs include the value of
time lost from work and leisure activities by family mem-
bers or friends who have forgone these activities when
providing care for patients.
The objective of this research was to estimate the total cost
of bacterial conjunctivitis in the United States. Both direct
and indirect costs were estimated from the societal or
overall healthcare system perspective.
Methods
Study Design
This study used an incidence-based burden-of-illness
framework to estimate the annual costs of bacterial con-
junctivitis in the United States. A bottom-up costing
approach was used to estimate the average direct and indi-
rect costs for the typical treatment and management of a
patient with bacterial conjunctivitis. These average costs
were then multiplied by the estimated annual incidence
rate to determine the total annual cost. Since a typical epi-
sode of bacterial conjunctivitis is approximately 10-14
days in duration no discounting was performed and all
costs are presented in 2007 US dollars.
Data Sources
A comprehensive literature search was performed using
Medline©, Embase©, Health Star©, NHSEED©, Cochrane©
and CINAHL® databases for articles on bacterial conjunc-
tivitis. The search strategy focused on articles related to the
clinical management of patients with bacterial conjuncti-
vitis, its epidemiology and costs associated with its treat-
ment. The keywords used to populate the literature search
included: bacterial conjunctivitis, conjunctivitis, treat-
ment and management, epidemiology, incidence, preva-
lence, health care costs and resource utilization. TheBMC Ophthalmology 2009, 9:13 http://www.biomedcentral.com/1471-2415/9/13
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search was restricted to English language articles pub-
lished within the last twenty years. In addition, a manual
literature search was also performed on citations in the
published articles to identify any relevant articles missed
in the initial search. Studies providing evidence of the
incidence of bacterial conjunctivitis were also used to
inform our analysis.
Physician Costs
Data on the office cost associated with visiting either a
pediatrician, general practitioner or ophthalmologist due
to bacterial conjunctivitis were derived from an examina-
tion of the Healthcare Common Procedure Coding Sys-
tem (HCPCS Codes) commonly used by the Center for
Medicare and Medicaid Services. These codes are based on
the Current Procedural Technology (CPT) codes devel-
oped by the American Medical Association to monitor
fees for various medical procedures. According to the
Center for Medicare and Medicaid Services, part of the
U.S. Department of Health and Human Services, the key
CPT codes of interest are: i) 99213 defined as "An office
other outpatient visit for the evaluation and management
of an established patient ... Usually, the presenting prob-
lem(s) are of low to moderate severity. Physicians typi-
cally spend 15 minutes face-to-face with the patient and/
or family" and ii) 92004 defined as "(Ophthalmological
services) Medical examination and evaluation with initia-
tion of diagnostic treatment program; comprehensive,
new patient, one or more visits" [24]. Data on the mean
values associated with each of these CPT fee codes for
2005 are presented in Table 1. The use of the Medicare
CPT fee codes was selected as it was most likely to approx-
imate the cost of seeing either a pediatrican, general phy-
sician or ophthalmologist across the United States.
Incidence of Bacterial Conjunctivitis
Data from the 2005 National Ambulatory Medical Care
Survey (NAMCS) were used to estimate the incidence rate
of bacterial conjunctivitis in the United States [25]. The
NAMCS is a national sample survey designed to meet the
need for objective, reliable information about the provi-
sion and use of ambulatory medical care services in the
United States. Data were obtained on patients' symptoms,
physicians' diagnoses, and medications ordered or pro-
vided. The survey also provides statistics on the demo-
graphic characteristics of patients and services provided,
including information on diagnostic procedures, patient
management, planned future treatment, geographic loca-
tion, racial composition and the extent of insurance cov-
erage.
Data from the NAMCS dataset were extracted using the
International Classification of Diseases 9th edition (ICD-
9) codes according to the following criteria. A case of bac-
terial conjunctivitis was considered to obtain at least one
of the following three ICD-9 fields: namely, 372.30 (Con-
junctivitis, unspecified), 372.03 (Conjunctivitis, mucopu-
rulent) or 372.00 (Acute conjunctivitis) [26]. This choice
of ICD-9 codes enabled the broadest possible definition
of a case of BC to be detected in the NAMCS database.
Other Direct Costs
Resource utilization and direct healthcare costs were
divided into three main categories; 1) Medical visit costs,
2) costs due to diagnostic tests and 3) the cost of prescrip-
tion drugs. Resource costs were calculated in US dollars at
2007 prices. The costs of diagnostic tests, such as bacterial
cultures, were also obtained from an examination of the
CMS data set using the relevant CPT fee code for conduct-
ing a bacterial culture, namely, CPT code number 87070,
while data on the medications prescribed for bacterial
conjunctivitis were obtained from the 2005 NAMCS data-
set [27]. Price data for ophthalmic antibiotics identified in
the NAMCS dataset were obtained from a standard refer-
ence for drug pricing, the Red Book (2004 Edition) as this
reflected prices at the start of 2005, the year which was
analysed in the NAMCS dataset [28].
Indirect Costs
In order to estimate indirect costs, it was assumed that for
each child's visit to the doctor's office, an adult accompa-
nied their child, resulting in lost time from work. By the
same token, adults seeking treatment for bacterial con-
junctivitis also lost earnings due to lost time from work. It
was assumed that a medical visit resulted in approxi-
mately two hours of lost productivity for adult patients or
Table 1: Primary Current Procedural Technology (CPT) codes used by Medicare and Medicaid Services mean values for 2005 *
CPT Code Mean Monetary Value (US $)
Outpatient visit physician examination 99213 53.50
Ophthalmological services initial visit 92004 131.35
Combination of values for 99213 and 92004 92.43
* Values were derived from an examination of the HCPC codes used by the Centre for Medicare and Medicaid Services (CMS) in the United States 
for the year 2005BMC Ophthalmology 2009, 9:13 http://www.biomedcentral.com/1471-2415/9/13
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adult caregivers of children seeking medical attention for
bacterial conjunctivitis. The U.S. Bureau of Labor Statistics
estimated the 2005 median weekly wage of all US workers
across all industries at $651 USD per week [29]. Using this
figure, the average hourly wage rate in the United States
for a forty hour work week equals $16.28 per hour USD.
In addition, one must take into account the fraction of
persons who were unemployed. Again according to the
U.S. Bureau of Labor Statistics during 2005, 63% of work-
ers were employed while 37% of were unemployed and or
retired [29]. For that fraction of the population which was
unemployed, a minimum wage rate of $ 5.15 per hour
was used to value the foregone earnings potential had
these persons been in paid employment [29]. Using these
figures, the indirect cost due to lost productivity was esti-
mated using the following formula ($ 16.28 × 0.63) + ($
5.15 × 0.37) = $10.26 + $ 1.91 = $ 12.17 per hour, or $
24.34 for the two hour period per patient per medical visit
due to bacterial conjunctivitis.
Economic Model
In order to estimate the total costs of bacterial conjuncti-
vitis (BC) in the United States, the following simplified
economic model was developed. Thus the total cost was
found by adding up both the total direct and total indirect
costs according to the following formula:
where;
α = Number of cases of BC seen by pediatricians as calcu-
lated using the NAMCS database;
β = Direct cost associated with a pediatric visit (mean phy-
sician visit cost + mean cost for lab tests + mean cost of
drug therapy)
γ = Indirect costs associated with a pediatric visit
δ = Number of cases of BC seen by all other physicians in
NAMCS database (Total BC Visits - Pediatrician visits
recorded in the NAMCS dataset)
λ = Direct cost associated with a visit to all other physi-
cians combined (mean of general physician visit cost plus
mean ophthalmologists visit cost) + mean cost for lab
tests + mean cost of drug therapy)
η = Indirect cost associated with a visit to all other physi-
cian visits combined.
Sensitivity Analysis
A deterministic sensitivity analysis approach recom-
mended by Briggs and Gray was conducted to test the
robustness of the economic model [30]. Both one-way
and two-way sensitivity analyses on the annual incidence
of bacterial conjunctivitis and treatment costs were per-
formed using a range of ± 20%. This range allowed suffi-
cient variation in both incidence rates and cost figures to
be explored in relation to the overall values obtained in
the base-case analysis.
Results
Incidence of Bacterial Conjunctivitis
Using the three ICD-9 codes of 372.30 (Conjunctivitis,
unspecified), 372.03 (Conjunctivitis, mucopurulent) or
372.00 (Acute conjunctivitis), the 2005 NAMCS data set
showed an estimated 4,016,544 visits to ambulatory phy-
sicians for bacterial conjunctivitis were made. Of these vis-
its, 2,270,268 (56.5%) were made by females and
1,746,276 (43.5%) by males [25]. Furthermore,
1,356,693 (33.77%) visits were made by patients less than
15 years of age to pediatricians [25]. It was assumed that
each visit represented a unique patient and there were no
repeat visits by the patient during the year. Thus, using a
2005 US base population of 296,507,061 the crude inci-
dence rate for bacterial conjunctivitis was estimated at
4,016,544/296,507,061 (1.3%) or roughly 135 cases per
10,000 annually [31].
Geographic, Racial and Insurance Coverage within the 
NAMCS dataset
Table 2 provides a distribution of key geographic, racial
and health insurance coverage variables for bacterial con-
junctivitis ambulatory physician visits within the 2005
NAMCS data set. The majority of 2005 bacterial conjunc-
tivitis cases (31%) occurred in the Southern region of the
U.S. followed by the Midwest (28%), West (23%) and
Northeast (18%) regions. With respect to the racial distri-
bution of bacterial conjunctivitis cases, the vast majority
of patients were listed as White (84%) followed by Asian
(10%), Black (5%) with the remainder (1%) listed as
being of other racial descent. The majority of bacterial
conjunctivitis cases in the 2005 NAMCS data set indicated
that they were covered by private insurance (62%) fol-
lowed by Medicaid/SCHIP (18%), Medicare (11%), with
the remainder listed as other.
It is interesting to note that the relative proportions of bac-
terial conjunctivitis cases in the NAMCS dataset is repre-
sentative of the geographic regions of the United States.
However, there appears to be some disparity in terms of
the racial mix of bacterial conjunctivitis cases. US Census
figures for the period 2006-2008 show that the acutal per-
centage population distribution of White Americans is
74.3%, while for Black Americans it is 12.3% of the total
population [32]. Equally interesting is that the percentage
of private insured patients captured in the NAMCS data-
set, i.e., at 51%. This is higher than the US national aver-
age of about 36% [33].
Total cost of BC Total Direct Costs  Total In =+ + (( * ) ( * )) αβ δλ d direct Costs (( * ) ( * )) αγ δη +BMC Ophthalmology 2009, 9:13 http://www.biomedcentral.com/1471-2415/9/13
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Prescribed Ophthalmic Antibiotic Drug Costs
The relative proportions of prescribed drugs for bacterial
conjunctivitis were estimated from the 2005 NAMCS data
set. Table 3 provides the most frequently prescribed oph-
thalmic antibiotics within the NAMCS data set. Using this
information, the costs of prescribed medications used to
treat bacterial conjunctivitis were determined from the
average wholesale prices listed in the 2004 Red Book[28].
Drug cost data are presented in Table 3 and form the basis
used to calculate the overall mean cost of prescribed med-
ications used to treat persons with bacterial conjunctivitis.
Direct and Indirect Costs
Table 4 provides the key unit costs used in the economic
model for the base-case and sensitivity analyses. These
cost data were obtained from a review of the CPT fee codes
for the costs associated with laboratory cultures for bacte-
rial conjunctivitis and used a CPT code of 87070 and the
indirect cost for lost productivity. As previously noted,
indirect costs were limited to lost wages due to time spent
seeking medical attention for the treatment of bacterial
conjunctivitis.
Base-Case Scenario
As can be seen from Table 5, the base-case scenario pro-
duced an estimated direct and indirect cost of treating
patients with bacterial conjunctivitis in the United States
of $ 491 million and $
97 million, respectively, for a total cost of $ 589 million.
The base case scenario assumes there is no variation in
either the annual incidence of bacterial conjunctivitis or
costs associated with the treatment and management of
patients with this condition.
One-way sensitivity analysis
Table 6 presents the results of a one-way sensitivity analy-
sis assuming a 20% variation in the annual incidence of
bacterial conjunctivitis while holding treatment costs con-
stant. This generates a cost range of $ 469 million to $ 705
Table 2: Distribution of key Geographic, Racial and Health Insurance Coverage Variables in the NAMCS data set 2005
VARIABLE OF INTEREST NUMBER (N = 4,016,544) PERCENTAGE (%)
Geographic Location
South 1,250,438 31.13%
Midwest 1,129,668 28.13%
West 912,634 22.72%
Northeast 723,804 18.02%
Racial Distribution
White 3,391,138 84.43%
Asian 384,943 9.58%
Black 188,948 4.70%
Other 51,515 1.29%
Insurance Coverage
Private insurance 2,484,655 61.86%
Medicaid/SCHIP* 718,271 17.88%
Medicare 451,384 11.24%
Other 362,234 9.02%
* State Children's Insurance Health ProgramBMC Ophthalmology 2009, 9:13 http://www.biomedcentral.com/1471-2415/9/13
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million. As with the base-case results, this figure is an
aggregate of the cost of treating both pediatric and adult
patients. Additionally, a two-way sensitivity analysis was
performed wherein the annual incidence of bacterial con-
junctivitis and the costs of treating and managing patients
with bacterial conjunctivitis were varied simultaneously.
Two-way sensitivity analysis
Table 7 presents the results of a simultaneous two-way
sensitivity analysis on both the annual incidence and
costs of treating and managing patients with bacterial con-
junctivitis. Assuming a 20% variation in both the annual
incidence of bacterial conjunctivitis and treatment costs
occurring simultaneously, the result is an estimated cost
range of $ 377 million to $ 857 million.
Both the one and two-way sensitivity analyses demon-
strate that given the economic model used, variations in
the incidence and in the unit costs have relatively large
effects on the overall total costs associated with treating
bacterial conjunctivitis in the United States. As such, our
model is sensitive to changes in both incidence and unit
cost data used to populate the economic model.
Table 3: Cost of Prescribed Ophthalmic Antibiotics
PRESCRIBED OPHTHALMIC ANTIBIOTIC PERCENTAGE (%) DISTRIBUTION WITHIN 
THE NAMCS DATASET
AVERAGE WHOLESALE PRICE
(RED BOOK 2004)
Sulfacetamide sodium 10%, 15 ml 19% $2.30
Moxifloxacin 0.5%, 3 ml 16% $46.80
Polymyxin/Trimethoprim
10,000 U/1 mg/ml, 10 ml
14% $17.42
Tobramycin 0.3%, 5 ml 14% $49.08
Tobramycin/Dexamethasone 0.3%-
0.1%, 5 ml
12% $59.88
Gentamicin 0.3%, 5 ml 11% $3.95
Ciprofloxacin 0.3%, 5 ml 6% $79.38
Neomycin/Polymyxin/Bacitracin
10,000 U/3.5 mg/400 U/g, 3.5 g
4% $15.77
Bacitracin 500 U/g, 3.5 g 3% $15.77
Sulfacetamide 10%, 3.5 g 1% $8.10
Levofloxacin 0.5%, 5 ml 1% $21.91
Weighted Average Price (US $) US $ 31.02
Table 4: Other Direct and Indirect Costs (Figures in US$)
RESOURCE CATEGORY MEAN COST PER VISIT (US $)
Direct Costs
Labs Tests for Cultures (CPT fee code = 87070)* $12.0375
Indirect Costs
Indirect Costs (Lost productivity of approximately two
hours per visit)
$24.34
*The mean cost for lab tests was obtained by surveying the CPT fee codes contained in the CMS database.BMC Ophthalmology 2009, 9:13 http://www.biomedcentral.com/1471-2415/9/13
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Discussion
In terms of situating the findings of the current study
within the context of other bacterial conjunctivitis epide-
miology studies, it is worth noting that NAMCS is a
national survey which was originally designed to meet the
need for objective, reliable information about the provi-
sion and use of ambulatory medical care services in the
United States. This said, the NAMCS survey was designed
to track medical conditions and prescribing patterns and
provides reliable estimates on the patient-physician
encounter. Using a refined ICD-9 classification for extract-
ing cases of bacterial conjunctivitis, it was possible to esti-
mate an annual bacterial conjunctivitis incidence rate of
135 per 10,000 in the United States. This U.S. bacterial
conjunctivitis incidence rate is less than one-half of the
rates reported in Norway (30 per 1,000) and the United
Kingdom (284 per 10,000) [13,14]. It is interesting to
note that even using a case definition of BC as any one of
the three ICD-9 codes (372.30 Conjunctivitis, unspeci-
fied), 372.03 (Conjunctivitis, mucopurulent) or 372.00
(Acute conjunctivitis) our analysis produced a signifi-
cantly lower incidence rate of BC in the US versus those
obtained in previous studies.
Our research raises questions as to why there is such a dif-
ference between the U.S. and European bacterial conjunc-
tivitis incidence rates. One possible source of disparity
may be due to study methodologies. In the European
studies the incidence rates were derived from actual clini-
cal data while the NAMCS figure was derived from a phy-
sician-patient encounter database using ICD-9 disease
classifications. A second source of distinction in incidence
rates may be due to history. The higher incidence rates in
the UK and Norway were reported in 1981 and 1991,
respectively. This represents a time span of 24 years from
the earliest study to this study which uses 2005 data. Since
1991 many new antibiotics have been marketed for the
treatment of bacterial conjunctivitis in the United States.
However, according to Hovding topical chloramphenicol
is still the mainstay of bacterial conjunctivitis therapy in
the United Kingdom and Europe [13].
Another factor which may explain the divergence in bac-
terial conjunctivitis incidence rates between Europe and
the U.S. is the medical practice patterns and physician's
attitudes towards the treatment of bacterial conjunctivitis.
American doctors may be more aggressive in treating bac-
terial conjunctivitis with antibiotics than their European
Table 5: Base-case analysis
VARIABLE OF INTEREST NUMBER
Total annual incidence of bacterial conjunctivitis(visits) 4,016,544
Total annual incidence of bacterial conjunctivitis
treated by pediatricians(visits)
1,356,693
Total annual incidence of bacterial conjunctivitis
treated by all other physicians(visits)
2,659,851
Total annual direct cost of bacterial conjunctivitis
treated by pediatricians(US$)
$130,988,709
Total annual indirect cost of bacterial conjunctivitis
treated by pediatricians(US$)
$33,021,908
Total annual direct cost of bacterial conjunctivitis
treated by all other physicians(US$)
$360,356,613
Total annual indirect cost of bacterial conjunctivitis
treated by all other physicians(US$)
$64,740,773
Total annual direct cost of bacterial conjunctivitis
treated by all medical personnel (pediatrician's plus all other physicians) (US$)
$491,345,323
Total annual indirect cost of bacterial conjunctivitis
treated by all medical personnel (pediatrician's plus all other physicians) (US$)
$97,762,681
Total annual direct and indirect cost of bacterial
conjunctivitis treated by all medical personnel
(pediatrician's plus all other physicians) (US$)
$589,108,004BMC Ophthalmology 2009, 9:13 http://www.biomedcentral.com/1471-2415/9/13
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counterparts. The effects of delayed antibacterial treat-
ment may influence the transmission rate of bacterial con-
junctivitis and consequently affect the incidence rates.
From a health economics perspective, it is possible to
compare the costs obtained in the current paper and to
examine them in relation to other cost of illness studies
which have been conducted for vision related disorders in
the United States and elsewhere during roughly the same
time period. Thus, assuming that the annual cost of treat-
ing and managing patients with bacterial conjunctivitis is
as given in the base-case analysis, i.e., $ 589 million, it is
possible to contrast this against other cost of illness stud-
ies in order to better understand its relative impact.
A review of cost of illness studies conducted in eye dis-
eases in 2004, found that the total financial cost of major
visual disorders among US residents over 40 years of age
was $ 35.4 billion, with $ 16.2 billion due to direct med-
ical costs, $ 11.1 billion due to other direct costs and $ 8
billion due to lost productivity [34]. The authors further
calculated that the direct medical costs for selected blind-
ing conditions in the United States amounted to: $ 6.8 bil-
lion for cataracts, $ 5.5 billion for refractive errors, $ 2.9
billion for glaucoma, $ 575 million for age related macu-
lar degeneration and $ 493 million for diabetic retinopa-
thy [34]. Similarly, in 2006, for example, Vitale et al
estimated that the annual direct cost of correcting distance
vision impairment in the United States was $ 3.8 billion
[35]. It has also been estimated by Frick et al that as much
as $ 5.5 billion is spent annually on the direct medical
care of blind individuals in the United States [36].
For international comparison purposes, a recent report on
the economic burden of bilateral neovascular age-related
macular degeneration in five countries, namely Canada,
Table 6: One-way sensitivity analysis varying Incidence of Bacterial Conjunctivitis
VARIABLE OF INTEREST 20% INCREASE IN INCIDENCE OF BC 20% DECREASE IN INCIDENCE OF BC
Total annual incidence of bacterial
conjunctivitis (visits)
4,819,853 3,213,235
Total annual incidence of bacterial
conjunctivitis treated by pediatricians
(visits)
1,628,032 1,085,354
Total annual incidence of bacterial
conjunctivitis treated by all other physicians 
(visits)
3,191,821 2,127,881
Total annual direct cost of bacterial
conjunctivitis treated by pediatricians
(US$)
$157,186,490 $104,790,929
Total annual indirect cost of bacterial
conjunctivitis treated by pediatricians
(US$)
$37,998,267 $26,417,516
Total annual direct cost of bacterial
conjunctivitis treated by all other physicians (US$)
$432,427,909 $288,285,318
Total annual indirect cost of bacterial
conjunctivitis treated by all other physicians (US$)
$77,688,923 $49,664,743
Total annual direct cost of bacterial
conjunctivitis treated by all medical personnel 
(pediatrician's plus all other physicians) (US$)
$589,614,399 $393,076,247
Total annual indirect cost of bacterial 
conjunctivitis treated by all medical personnel 
(pediatrician's plus all other physicians) (US$)
$115,687,190 $76,082,259
Total annual direct and indirect cost
of bacterial conjunctivitis treated by all medical 
personnel (pediatrician's plus all other physicians) 
(US$)
$705,301,589 $469,158,505BMC Ophthalmology 2009, 9:13 http://www.biomedcentral.com/1471-2415/9/13
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France, Germany, Spain and the UK found that the annual
societal cost due blindness ranged from 268 to 1311 mil-
lion Euros [37]. Equally, Happich et al found that the eco-
nomic burden of diabetic retinopathy in Germany in
2002 was 3.51 billion Euros if measured from the societal
perspective [38]. Thus when viewed against the above
studies, the cost of illness due to bacterial conjunctivitis is
on a par with other more chronic vision problems, such as
ARMD and diabetic retinopathy which affect relatively
small numbers of individuals on an annual basis but
accrue greater per patient costs. Bacterial conjunctivitis, by
contrast, accrues relatively smaller per patient costs, yet it
affects a far greater number of persons on an annual basis
than does ARMD or diabetic retinopathy.
Moreover, in comparing the bacterial conjunctivitis cost
findings with the above mentioned cost of illness studies
in vision and eye disease, it is important to remember that
our study sought to conservatively measure both the
direct and indirect costs associated with seeking treatment
due to bacterial conjunctivitis. Further refinement of both
the direct and indirect costs data would undoubtedly
Table 7: Two-way sensitivity analysis varying both incidence and cost of treatment and management of patients with bacterial 
conjunctivitis
VARIABLE OF INTEREST 20% INCREASE IN INCIDENCE OF BC 
PLUS
20% INCREASE IN COSTS OF 
TREATING AND MANAGING 
PATIENTS WITH BC
20% DECREASE IN INCIDENCE OF BC 
PLUS
20% DECREASE IN COSTS OF 
TREATING AND MANAGING 
PATIENTS WITH BC
Total annual incidence of
bacterial conjunctivitis (visits)
4,819,853 3,213,235
Total annual incidence of
bacterial conjunctivitis treated by pediatricians 
(visits)
1,628,032 1,085,354
Total annual incidence of
bacterial conjunctivitis treated by all other 
physicians (visits)
3,191,821 2,127,881
Total annual direct cost of
bacterial conjunctivitis treated by pediatricians 
(US$)
$188,623,788 $83,832,743
Total annual indirect cost of
bacterial conjunctivitis treated by pediatricians 
(US$)
$47,554,815 $21,131,842
Total annual direct cost of
bacterial conjunctivitis treated by all other 
physicians (US$)
$528,501,721 $230,628,254
Total annual indirect cost of
bacterial conjunctivitis treated by all other 
physicians (US$)
$93,233,091 $41,429,843
Total annual direct cost of
bacterial conjunctivitis treated by all medical 
personnel (pediatrician's plus all other 
physicians) (US$)
$717,125,509 $314,460,997
Total annual indirect cost of
bacterial conjunctivitis treated by all medical 
personnel (pediatrician's plus all other 
physicians) (US$)
$140,787,906 $62,561,685
Total annual direct and indirect
cost of bacterial conjunctivitis treated by all 
medical personnel (pediatrician's plus all other 
physicians) (US$)
$857,913,415 $377,022,683BMC Ophthalmology 2009, 9:13 http://www.biomedcentral.com/1471-2415/9/13
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increase the overall total costs attributable to bacterial
conjunctivitis. The current analysis, for example, used a
highly conservative estimate of the indirect costs associ-
ated with lost productivity due to seeking medical atten-
tion for the treatment of bacterial conjunctivitis, taking
into account only lost wages and did not include other
indirect costs such as travel, transportation and parking
costs which were difficult to fully quantify with any degree
of precision. Our findings must therefore be regarded as a
highly conservative estimate of the annual costs due to the
treatment and management of patients with bacterial con-
junctivitis in the United States.
Future Study
One area for future study would be to investigate if the
introduction of newer more potent antibiotics has exerted
any influence over bacterial conjunctivitis incidence rates.
There is evidence that the fourth generation fluoroqui-
nolone, and moxifloxacin, exhibited better efficacy com-
pared to polymyxin/trimethoprim, an older combination
antibiotic agent [39]. Cost-effectiveness evaluations of
this question, looking at total costs, would be useful as
would those studies which attempt to model the indirect
costs associated with microbial drug resistance, though
this topic is far beyond the scope the present analysis.
Conclusion
The burden of bacterial conjunctivitis is considerable both
in absolute terms, i.e., is, the number of patients treated
on an annual basis and in economic terms, i.e., the direct
costs of physician's visits, drug therapy, diagnostic tests
and the indirect costs of lost earnings. Infectious diseases
pose a unique set of problems relating to the burden of ill-
ness studies because the transmission rate of the illness to
susceptible persons directly influences the incidence rate
of the disease. Since costs are sensitive to the incidence
rate, anything that affects the contagious period of the
infected population can influence the incidence rate and
consequently the cost-of-illness. The use of potent antibi-
otics may reduce the contagious period of the infected
population thereby reducing the transmission of the dis-
ease to the susceptible population. Consequently, there
may well be a potential role for use of potent antibiotics,
such as the newer fourth-generation fluoroquinolones to
reduce the aggregate cost of bacterial conjunctivitis, espe-
cially those costs related to indirect costs, even if the direct
drug costs may be higher in the first instance.
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